The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COSTEM 2019 | AML: mutant IDH1 inhibitor HMS-101
Michael Heuser, MD, Hannover Medical School, Hannover, Germany, discusses the aims, methods and findings of his study of the in vivo efficacy of the mutant IDH1 inhibitor HMS-101 and the structural resolution of a distinct binding site. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.
